Arcutis Biotherapeutics (ARQT) Revenue (2022 - 2026)

Arcutis Biotherapeutics' Revenue history runs 5 years deep, the most recent figure standing at $105.4 million for Q1 2026.

• In Q1 2026, Revenue rose 65.08% year-over-year to $105.4 million; the TTM figure through Mar 2026 stood at $415.6 million (up 99.04% YoY), while the FY2025 annual figure was $376.1 million, up 125.81% from the prior year.
• Revenue for Q1 2026 stood at $105.4 million, down from $129.5 million in the prior quarter.
• The five-year high for Revenue was $129.5 million in Q4 2025, with the low at $725000.0 in Q3 2022.
• The 5-year median for Revenue is $43.9 million (2023), against an average of $49.3 million.
• The sharpest annual moves came in 2023 and 2024: Revenue surged 5156.41% in 2023, then rose 17.44% in 2024.
• Arcutis Biotherapeutics' Revenue stood at $3.0 million in 2022, then soared by 1384.16% to $43.9 million in 2023, then jumped by 57.83% to $69.4 million in 2024, then jumped by 86.71% to $129.5 million in 2025, then retreated by 18.61% to $105.4 million in 2026.
• Business Quant data shows ARQT's Revenue at $105.4 million in Q1 2026, $129.5 million in Q4 2025, and $99.2 million in Q3 2025.